Synthesis, structure-activity relationships and brain uptake of a novel series of benzopyran inhibitors of insulin-regulated aminopeptidase

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1368-1377

  Mountford, Simon J ^a   Albiston, Anthony L ^b   Charman, William N ^c   Ng, Leelee ^d   Holien, Jessica K ^e   Parker, Michael W ^e,f   Nicolazzo, Joseph A ^a   Thompson, Philip E ^a   Chai, Siew Yeen ^d  

^a MONASH UNIVERSITY   (Australia)

^b VICTORIA UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPYRAN DERIVATIVE; ENZYME INHIBITOR; HFI 142; HFI 419; HFI 435; HFI 437; INSULIN REGULATED AMINOPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME INHIBITION; FEAR; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOLECULAR MODEL; NONHUMAN; RAT; SPATIAL LEARNING; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION;

AMINOPEPTIDASES; ANIMALS; BENZOPYRANS; BRAIN; CELL LINE; ENZYME INHIBITORS; HUMANS; INSULIN; MAGNETIC RESONANCE SPECTROSCOPY; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896837126     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401540f     Document Type: Article

References (29)

1. Albiston, A. L.; Peck, G. R.; Yeatman, H. R.; Fernando, R.; Ye, S.; Chai, S. Y. Therapeutic targeting of insulin-regulated aminopeptidase: heads and tails? Pharmacol. Ther. 2007, 116, 417-427
2. Braszko, J. J.; Kupryszewski, G.; Witczuk, B.; Wisniewski, K. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats Neuroscience 1988, 27, 777-783
3. Wright, J. W.; Miller-Wing, A. V.; Shaffer, M. J.; Higginson, C.; Wright, D. E.; Hanesworth, J. M.; Harding, J. W. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory Brain Res. Bull. 1993, 32, 497-502
4. Braszko, J. J. Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV Peptides 2004, 25, 1195-1203
5. Wright, J. W.; Stubley, L.; Pederson, E. S.; Kramar, E. A.; Hanesworth, J. M.; Harding, J. W. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning J. Neurosci. 1999, 19, 3952-3961
6. Lee, J.; Albiston, A. L.; Allen, A. M.; Mendelsohn, F. A. O.; Ping, S. E.; Barrett, G. L.; Murphy, M.; Morris, M. J.; McDowall, S. G.; Chai, S. Y. Effect of intracerebroventricular injection of AT4 receptor ligands, Nle1-angiotensin IV and LVv-hemorphin 7, on spatial learning in rats Neuroscience 2004, 124, 341-349
7. Wright, J. W.; Clemens, J. A.; Panetta, J. A.; Smalstig, E. B.; Weatherly, L. A.; Kramar, E. A.; Pederson, E. S.; Mungall, B. H.; Harding, J. W. Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats Brain Res. 1996, 717, 1-11
8. Olson, M. L.; Olson, E. A.; Qualls, J. H.; Stratton, J. J.; Harding, J. W.; Wright, J. W. Norleucine1-angiotensin IV alleviates mecamylamine-induced spatial memory deficits Peptides 2004, 25, 233-241
9. Pederson, E. S.; Harding, J. W.; Wright, J. W. Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog Regul. Pept. 1998, 74, 97-103
10. Pederson, E. S.; Krishnan, R.; Harding, J. W.; Wright, J. W. A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits Regul. Pept. 2001, 102, 147-156
11. Albiston, A. L.; Pederson, E. S.; Burns, P.; Purcell, B.; Wright, J. W.; Harding, J. W.; Mendelsohn, F. A.; Weisinger, R. S.; Chai, S. Y. Reversal of scopolamine-induced memory deficits by LVV-hemorphin 7 in rats in the passive avoidance and Morris water maze paradigms Behav Brain Res 2004, 154, 239-243
12. Wisniewski, K.; Borawska, M.; Car, H. The effect of angiotensin II and its fragments on post-alcohol impairment of learning and memory Pol. J. Pharmacol. 1993, 45, 23-29
13. Axén, A.; Lindeberg, G.; Demaegdt, H.; Vauquelin, G.; Karlen, A.; Hallberg, M. Cyclic insulin-regulated aminopeptidase (IRAP)/AT4 receptor ligands J. Pept. Sci. 2006, 12, 705-713
14. Axén, A.; Andersson, H.; Lindeberg, G.; Rönnholm, H.; Kortesmaa, J.; Demaegdt, H.; Vauquelin, G.; Karlén, A.; Hallberg, M. Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor J. Pept. Sci. 2007, 13, 434-444
15. Andersson, H.; Demaegdt, H.; Vauquelin, G.; Lindeberg, G.; Karlén, A.; Hallberg, M. Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2 Bioorg. Med. Chem. 2008, 16, 6924-6935
16. Lukaszuk, A.; Demaegdt, H.; Szemenyei, E.; Tóth, G.; Tymecka, D.; Misicka, A.; Karoyan, P.; Vanderheyden, P.; Vauquelin, G.; Tourwé, D. Beta-homo-amino acid scan of angiotensin IV J. Med. Chem. 2008, 51, 2291-2296
17. Andersson, H.; Demaegdt, H.; Vauquelin, G.; Lindeberg, G.; Karlen, A.; Hallberg, M.; Erdelyi, M.; Hallberg, A. Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP) J. Med. Chem. 2010, 53, 8059-8071
18. Andersson, H.; Demaegdt, H.; Johnsson, A.; Vauquelin, G.; Lindeberg, G.; Hallberg, M.; Erdelyi, M.; Karlen, A.; Hallberg, A. Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis J. Med. Chem. 2011, 54, 3779-3792
19. Albiston, A. L.; Morton, C. J.; Ng, H. L.; Pham, V.; Yeatman, H. R.; Ye, S.; Fernando, R. N.; De Bundel, D.; Ascher, D. B.; Mendelsohn, F. A.; Parker, M. W.; Chai, S. Y. Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase FASEB J. 2008, 22, 4209-4217
20. Kemnitzer, W.; Sirisoma, N.; Jiang, S.; Kasibhatla, S.; Crogan-Grundy, C.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of N-aryl-9-oxo-9H-fluorene-1- carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring Bioorg. Med. Chem. Lett. 2010, 20, 1288-1292
21. Balalaie, S.; Abdolmohammadi, S.; Bijanzadeh, H. R.; Amani, A. M. Diammonium hydrogen phosphate as a versatile and efficient catalyst for the one-pot synthesis of pyrano[2,3-d]pyrimidinone derivatives in aqueous media Mol. Diversity 2008, 12, 85-91
22. Jin, G.; Zhang, C.; Ido, T.; Goto, S. Synergetic effect of tetrabutylammonium bromide and polyethylene glucol as a phase transfer catalysts in third liquid phase for benzyl-n-butyl ester synthesis Catal. Lett. 2004, 98, 107-111
23. Albiston, A. L.; Pham, V.; Ye, S.; Ng, L.; Lew, R. A.; Thompson, P. E.; Holien, J. K.; Morton, C. J.; Parker, M. W.; Chai, S. Y. Phenylalanine-544 plays a key role in substrate and inhibitor binding by providing a hydrophobic packing point at the active site of insulin-regulated aminopeptidase Mol. Pharmacol. 2010, 78, 600-607
24. Clark, D. E. In silico prediction of blood-brain barrier permeation Drug Discovery Today 2003, 8, 927-934
25. Thunnissen, M. M.; Nordlund, P.; Haeggstrom, J. Z. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation Nat. Struct. Biol. 2001, 8, 131-135
26. Clark, M.; Cramer, R. D.; Van Opdenbosch, N. Validation of the general purpose tripos 5.2 force field J. Comput. Chem. 1989, 10, 982-1012
27. McGann, M.; Almond, H.; Nicholls, A.; Grant, J. A.; Brown, F. Gaussian docking functions Biopolymers 2003, 68, 76-90
28. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds J. Med. Chem. 2001, 44, 2490-2497
29. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283, 46-58